US4518527A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polypeptides related to the pre-acetylcholine receptor-α of the electric organ of Torpedo californica
Assignee: Mitsubishi Chemical Corp
•
Filing: 1983-08-16
•
Granted: 1985-05-21
•
Expires: 2003-08-16
Abstract
Abstract Polypeptides having partial or complete amino acid sequences related to the pre-acetylcholine receptor- alpha of the electric organ Torpedo californica are disclosed. These polypeptides having AChR antigenic properties are useful for the production and purification of antibodies to the acetylcholine receptor (AChR) as well as for the diagnosis of myastenia gravis (MG).
Inventors
- 👤 Shosaku Numa
- 👤 Noboru Yanaihara
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 23:52
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/70571; C07K14/46; Y; Y10; Y10S; Y10S530/00; Y10S530/868
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
66 words
a polypeptide consisting essentially of an amino acid sequence which is at least one member selected from the group consisting of: (a) Ser-Glu-His-Glu-Thr-Arg, (b) Gly-Ile-Lys-Ile-Arg, (c) Arg-Leu-Pro-Ser-Asp-Asp, (d) Asn-Asn-Ala-Asp-Gly-Asp, (e) Glu-Ser-Asp-Arg-Pro-Asp, (f) Lys-Asp-Tyr-Arg-Gly, (g) Thr-Asp-Ser-Gly-Glu-Lys, (h) Lys-Arg-Ala-Ser-Lys-Glu-Lys-Gln-Glu-Asn-Lys, (i) Lys-Asn-Pro-Asp-Val-Lys, (j) Lys-Ser-Asp-Glu-Glu-Ser, (k) Asp-Tyr-Gly-Gly-Ile-Lys, (l) Asp-Thr-Pro-Tyr-Leu-Asp, (m) Arg-Ser-Pro-Ser-Thr-His; and (n) at least one member selected from a pharmaceutically-acceptable acid-addition salt of amino acid sequences (a) to (m).
Claim 2
Dependent Claim
66 words
a polypeptide consisting essentially of an amino acid sequence which is at least one member selected from the group consisting of: (a) Ser-Glu-His-Glu-Thr-Arg, (b) Gly-Ile-Lys-Ile-Arg, (c) Arg-Leu-Pro-Ser-Asp-Asp, (d) Asn-Asn-Ala-Asp-Gly-Asp, (e) Glu-Ser-Asp-Arg-Pro-Asp, (f) Lys-Asp-Tyr-Arg-Gly, (g) Thr-Asp-Ser-Gly-Glu-Lys, (h) Lys-Arg-Ala-Ser-Lys-Glu-Lys-Gln-Glu-Asn-Lys, (i) Lys-Asn-Pro-Asp-Val-Lys, (j) Lys-Ser-Asp-Glu-Glu-Ser, (k) Asp-Tyr-Gly-Gly-Ile-Lys, (l) Asp-Thr-Pro-Tyr-Leu-Asp, (m) Arg-Ser-Pro-Ser-Thr-His; and (n) at least one member selected from a pharmaceutically-acceptable acid-addition salt of amino acid sequences (a) to (m).
Claim 3
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Ser-Glu-His-Glu-Thr-Arg, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 4
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Gly-Ile-Lys-Lys-Ile-Arg, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 5
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Arg-Leu-Pro-Ser-Asp-Asp, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 6
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Asn-Asn-Ala-Gly-Asp, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 7
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Glu-Ser-Asp-Arg-Pro-Asp, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 8
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Lys-Asp-Tyr-Arg-Gly, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 9
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Thr-Asp-Ser-Gly-Glu-Lys, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 10
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Lys-Arg-Ala-Ser-Lys-Glu-Lys-Gln-Glu-Asn-Lys, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 11
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Lys-Asn-Pro-Asp-Val-Lys, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 12
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Lys-Ser-Asp-Glu-Glu-Ser, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 13
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Asp-Tyr-Gly-Gly-Ile-Lys, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 14
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Asp-Thr-Pro-Tyr-Leu-Asp, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 15
Dependent Claim
18 words
The polypeptide of claim 1 wherein said amino acid sequence is Arg-Ser-Pro-Ser-Thr-His, or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 16
Dependent Claim
65 words
The polypeptide of claim 1 which has bound to one of its termini human albumin, bovine albumin, collagen, hemocyanin, fibrinogen, human erythrocyte, poly-glutamic acid, polylysine, a lower alkyl of C 1-10 , a lower acyl of C 1-10 , an amino group, a lower alkyl amino of C 1-10 , a di-lower alkyl amino of C 1-10 or a lower alkoxy of C 1-10 .
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-05-20 | 1988-11-19 | 1989-05-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-05-20 | 1992-11-19 | 1993-05-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-05-20 | 1996-11-19 | 1997-05-21 | $7700.00 | Window Closed / Lapsed |